<DOC>
	<DOCNO>NCT00796471</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics 2 extended-release ( ER ) formulation 2 mg-eq paliperidone comparison 2 mg immediate-release ( IR ) paliperidone oral solution evaluate effect food pharmacokinetics ER formulation . Additional objective compare pharmacodynamic effect ( postural change blood pressure heart rate ) , safety , tolerability evaluate addition explore relationship CYP2D6 CYP3A4/5genotype paliperidone exposure .</brief_summary>
	<brief_title>A Pharmacokinetics Pharmacodynamics Study Under Fasting Fed Conditions With Paliperidone Extended-release Immediate-release Formulations</brief_title>
	<detailed_description>This study design single-center , open-label , randomize , 5 treatment-period , crossover study healthy adult . The study consist screen phase treatment phase volunteer receive 5 treatment study drug random order separate washout period least 7 14 day . Treatments consist single oral dose : A ) paliperidone ER pellet formulation , ( 2 mg-eq ) 1 capsule 2.5 mg , fast ; B ) formulation A food ; C ) paliperidone-coated ER OROS formulation ( 2 mg eq ) 2 tablet 2 mg , fast ; D ) formulation C food ; E ) IR paliperidone oral solution , 2 mg ( 2 mL ) 1 mg/mL solution , fast . Alternative paliperidone ER formulation develop aim increase bioavailability without compromise favorable effect orthostatic hypotension see ER OROS paliperidone . Therefore , study , pharmacokinetic pharmacodynamic property , well effect food , 2 alternative paliperidone ER formulation use different mechanism achieve extend release drug investigate : multiparticulate ER capsule formulation , contain coat pellet comprise 3 coat layer , immediate extend drug-release property ( pellet formulation ; drug ratio extended- versus immediate-release layer : 9:1 ) , OROS trilayer longitudinally compress tablet formulation ( Push-Pull delivery system ) ( overcoated-OROS formulation ) . Safety tolerability monitor throughout study . Single dose paliperidone ER pellet formulation , ( 2 mg-eq ) 1 capsule 2.5 mg , fast ; paliperidone ER pellet formulation , ( 2 mg-eq ) 1 capsule 2.5 mg food ( high-fat breakfast ) ; paliperidone-coated OROS ER formulation ( 2 mg-eq ) 2 tablet 2 mg , fast ; paliperidone-coated OROS ER formulation ( 2 mg-eq ) 2 tablet 2 mg food ( high-fat breakfast ) ; IR paliperidone oral solution , 2 mg ( 2 mL ) 1 mg/mL solution , fast .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Acceptable weight define body mass index ( weight [ kg ] /height ( ) ² ) range 18.0 28.0 kg/m² , inclusive Normotensive supine ( 5 minute ) blood pressure range 100 140 mmHg systolic , inclusive , 60 90 mmHg diastolic , inclusive Healthy basis prestudy physical examination , medical history , electrocardiogram , laboratory result blood biochemistry , hematology urinalysis perform within 21 day first dose . If result biochemistry , hematology urinalysis test within laboratory 's reference range volunteer include investigator judge deviation clinically significant . For liver function test ( alanine transaminase , aspartate transaminase , bilirubin ) , value must contain within 2 time upper limit normal laboratory reference range renal function test , value must within normal laboratory reference range Women must postmenopausal least 1 year , surgically sterile , practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization discretion investigator , total abstinence ) entry throughout study , well negative serum pregnancy test screening . To ensure continued eligibility , woman must negative urine test dose study drug ( Day 1 period ) . Known allergy history significant hypersensitivity heparin Recent history alcohol substance abuse . Test positive urine drug screen screen urine drug screen alcohol breath test Day 1 Period 1 Relevant history cardiovascular , respiratory neuropsychiatric , renal , hepatic , gastrointestinal ( include surgery , malabsorption problem ) , endocrine , immunologic diseases A decrease great equal 20 mmHg systolic blood pressure 3 minute stand , symptom lightheadedness , dizziness faint upon stand screen Positive result serology test ( hepatitis B , C HIV ) History smoking use nicotinecontaining substance within last 2 month , determine medical history and/or volunteer 's verbal report . ( Volunteers must agree refrain use throughout study . ) Drug allergy risperidone , paliperidone , excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Mood Disorders</keyword>
	<keyword>Antipsychotic drug</keyword>
	<keyword>Paliperidone ER</keyword>
</DOC>